tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO), Cocrystal Pharma (COCP) and C4 Therapeutics (CCCC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Perrigo Company (PRGOResearch Report), Cocrystal Pharma (COCPResearch Report) and C4 Therapeutics (CCCCResearch Report) with bullish sentiments.

Perrigo Company (PRGO)

In a report released yesterday, Chris Schott from J.P. Morgan maintained a Buy rating on Perrigo Company, with a price target of $54.00. The company’s shares closed last Tuesday at $36.12, close to its 52-week low of $34.53.

According to TipRanks.com, Schott is a 3-star analyst with an average return of 1.6% and a 51.0% success rate. Schott covers the Healthcare sector, focusing on stocks such as Horizon Therapeutics, Coherus Biosciences, and Merck & Company.

Perrigo Company has an analyst consensus of Moderate Buy, with a price target consensus of $59.00.

See the top stocks recommended by analysts >>

Cocrystal Pharma (COCP)

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma, with a price target of $5.00. The company’s shares closed last Tuesday at $0.52, close to its 52-week low of $0.45.

According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 15.6% and a 33.0% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Ayala Pharmaceuticals, and Onconova Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cocrystal Pharma with a $4.50 average price target.

C4 Therapeutics (CCCC)

J.P. Morgan analyst Eric Joseph maintained a Buy rating on C4 Therapeutics yesterday and set a price target of $22.00. The company’s shares closed last Tuesday at $8.76, close to its 52-week low of $7.51.

According to TipRanks.com, Joseph is a 1-star analyst with an average return of -1.3% and a 50.0% success rate. Joseph covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Karyopharm Therapeutics, and Enanta Pharmaceuticals.

Currently, the analyst consensus on C4 Therapeutics is a Moderate Buy with an average price target of $39.75, implying a 397.5% upside from current levels. In a report issued on April 8, Brookline Capital Markets also maintained a Buy rating on the stock with a $84.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PRGO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed